Imaging Biometrics Ltd., through its subsidiaries, provides clinical treatments to patients in the field of medical imaging diagnostics in the United Kingdom, Switzerland, European Union, and the United States. It operates through Holding Company, Medical Software, and Oral Gallium Maltolate (GaM) segments. The company develops ready-to-use software applications for the healthcare industry comprising IB Clinic for all IB software platforms; IB Neuro, a MR DSC perfusion processing platform; IB Delta Suite, which creates Delta T1 maps from routine MR exams; IB DCE and IB Diffusion that provide whole body insights on blood flow and water diffusion; StoneChecker and Liver Surface Nodularity, which are computed tomography processing applications designed to assist clinicians in the non-invasive assessment of kidney stones and liver health; IB ASL to measure cerebral blood flow to assess stroke, dementia, and other neurological conditions; IB Zero G, a technology designed to eliminate the need for gadolinium contrast agents in standard imaging; and IB Nimble, which supports healthcare providers through virtual collaboration among clinicians. It is also involved in the development of IB003, a gallium maltolate drug candidate in Phase 1 clinical trial for the treatment of glioblastoma. In addition, the company offers consulting services. The company was formerly known as IQ-AI Limited and changed its name to Imaging Biometrics Ltd. in May 2025. Imaging Biometrics Ltd. was incorporated in 1965 and is based in Saint Helier, Jersey.